Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population

Li, Minrui; Zhang, Shenghong; Wu, Yanqin; Ye, Junzhao; Cao, Xu; Liu, Jie; Sun, Yanhong; Zhong, Bihui

doi:10.1007/s10620-015-3564-5

Cited by 20 publications

(16 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[13] Furthermore, Li et al found female, general and abdominal obesity, and hypertension were independent predictors for IR in NAFLD patients. [14] Dixon's study showed insulin resistance and systemic hypertension, features of the metabolic syndrome, are independently associated with advanced forms of NAFLD. [15]…”

Section: Discussionmentioning

confidence: 99%

Metabolic characteristics of obese children with fatty liver

Zhao

Wang

2019

Medicine

View full text Add to dashboard Cite

To investigate metabolic differences between simple obese children and those comorbid with fatty liver disease. Obese children hospitalized in our center from 2014 to 2016 were included and divided into simple obese group and obese with fatty liver group by ultrasound-based diagnosis of fatty liver. Epidemiology data and serum biochemical studies were recorded. Body Mass Index (BMI) and homeostasis model insulin resistance index (HOMA-IR) were calculated accordingly. A total of 186 obese children were enrolled in this study, including 93 cases of obese children and 93 obese patients’ comorbid with fatty liver. The proportion of male, age, waist circumference (WC), BMI, fasting blood-glucose (FBG), glycosylated hemoglobin A1c (HbA1c), fasting insulin (FINS), and HOMA-IR were significantly higher in obese patients with fatty liver ( P <.05). Age and BMI were found to be independent risk factors for fatty liver disease (OR >1, P <.05). Among obese children, male and elder patients and individuals with higher uric acid are more susceptible to fatty liver.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic characteristics of obese children with fatty liver

Zhao

Wang

2019

Medicine

View full text Add to dashboard Cite

show abstract

“…The homeostasis model of assessment for insulin resistance (HOMA-IR) was calculated as [fasting plasma glucose level (mmol/l) × fasting plasma insulin level (μU/ml)]/22.5. 21 After the initial visit, the above anthropometric indexes and biochemical indicators were measured at 1, 3 and 6 months with a maximum delay of 1 month at each arranged visit.…”

Section: Methodsmentioning

confidence: 99%

Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction

et al. 2019

Therap Adv Gastroenterol

Self Cite

View full text Add to dashboard Cite

Background: The liver effect of orlistat as a weight control treatment in patients with nonalcoholic fatty liver disease (NAFLD) with obesity remains undetermined. This study quantified liver fat improvement by orlistat in a Chinese cohort with NAFLD accompanied by obesity, diagnosed by a lower body mass index threshold than that for White patients. Materials and methods: We conducted a parallel-group, open-label, 24-week, randomized clinical trial registered at the Chinese Clinical Trial Registry (ChiCTR-IPR-17012258). Obese participants with NAFLD were randomized 1:1.5 to the intervention group with orlistat or conventional care. Liver fat quantification was assessed by magnetic resonance imaging-based proton density fat fraction with Dixon sequence. Results: Overall, 170 ( n = 68, orlistat 120 mg three times/day and n = 102, conventional therapy) and 130 patients with NAFLD ( n = 56, orlistat and n = 74, conventional therapy) were included for intention-to-treat (ITT) and per-protocol (PP) analysis, respectively. Orlistat reduced liver fat content to a greater degree than conventional care [−5.45% versus −1.96%, p < 0.001 (ITT analysis) and −6.66% versus −2.68%, p < 0.001 (PP analysis)]. The 6-month rate of decrease in steatosis grades was higher in the orlistat group [45.6% versus 22.5% (ITT analysis), 57.4% versus 30.3% (PP analysis), both p < 0.001]. Multivariate logistic regression analysis identified orlistat treatment [odds ratio (OR) = 2.4; 95% confidence interval (CI) 1.1–5.6, p = 0.036] as an independent predictor of steatosis improvement. Among patients with orlistat therapy, weight loss (OR = 1.2, 95% CI 1.1–1.4, p = 0.040) and severe steatosis (OR = 6.7, 95% CI: 1.1–40.3, p = 0.03) remained predictive of steatosis improvement. Conclusions: Orlistat can effectively promote steatosis improvement and may serve as a treatment option for controlling NAFLD. Chinese Clinical Trial Registry identifier: ChiCTR-IPR-17012258

show abstract

“…Impaired suppression of hepatic glucose production is associated with increased intrahepatic triglyceride accumulation, which is a hallmark of NAFLD [44,45]. Most patients with type 2 diabetes experience NAFLD, and NAFLD patients have a higher risk of insulin resistance compared to healthy controls [46,47]. It is suggested that intrahepatic triglyceride content is a strong predictor of insulin action in the liver, skeletal muscle, and adipose tissues [44,45].…”

Section: Discussionmentioning

confidence: 99%

Honokiol Improves Insulin Resistance, Hepatic Steatosis, and Inflammation in Type 2 Diabetic db/db Mice

Kim

Jung

2019

IJMS

View full text Add to dashboard Cite

This study focuses on the effect of honokiol (HON) on glucose homeostasis, insulin resistance, dyslipidemia, hepatic steatosis, and inflammation in type 2 diabetic db/db mice. Male C57BL/KsJ-db/db mice were fed a normal diet with or without HON (0.02%, w/w) or pioglitazone (PIO, anti-diabetic agent, 0.01%, w/w) for 5 weeks. Blood biomarker, tissue morphology and enzymatic and genetic parameters were determined. PIO significantly decreased food intake, fasting blood glucose, and glycosylated hemoglobin (HbA1c) levels, but markedly increased body weight, adipose tissue weight, and plasma leptin levels. HON did not significantly affect food intake, body weight, or levels of plasma leptin and blood glucose. However, HON led to significant decreases in adipose tissue weight, plasma insulin, blood HbA1c and HOMA-IR levels and improved glucose tolerance. The anti-diabetic and anti-adiposity effects of HON were partially related to the inhibition of gluconeogenic enzymes and their mRNA expression in the liver; and the inhibition of lipogenic enzymes in adipose tissue, respectively. Unlike PIO, HON did not affect dyslipidemia, but ameliorated hepatic steatosis by inhibiting hepatic lipogenic enzymes activity. Moreover, HON exhibited anti-inflammatory effects similar to PIO. These results suggest that HON can protect against type 2 diabetes by improving insulin resistance, glucose and lipid metabolism, and inflammation.

show abstract

Prevalence of Insulin Resistance in Subjects with Nonalcoholic Fatty Liver Disease and Its Predictors in a Chinese Population

Abstract: Chinese NAFLD patients are susceptible to IR. Female sex, general and abdominal obesity, and hypertension were independent predictors for IR in NAFLD patients. FPI is an optimal predictor for IR.

Cited by 20 publications

References 40 publications

Metabolic characteristics of obese children with fatty liver

Metabolic characteristics of obese children with fatty liver

Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction

Honokiol Improves Insulin Resistance, Hepatic Steatosis, and Inflammation in Type 2 Diabetic db/db Mice

Contact Info

Product

Resources

About